For Immediate Release: September 20, 2017
513-579-9911 x 12523
Medpace is a Finalist for the 13th Annual Scrip Awards, 2017 in the Category of Best Contract Research Organization – Full Service Provider
CINCINNATI —September 20, 2017– Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) has been named as a finalist for the 13th Annual Scrip Awards. The Scrip Awards is an industry event, acknowledging the important work of the biopharmaceutical industry’s best and brightest leaders and companies.
Medpace was chosen as a finalist in the category of Best Full Service CRO, after the review and selection by 16 independent industry judges. This recognition reflects Medpace’s commitment to excellence in conducting full service global studies and its mission of accelerating the global development of safe and effective medical therapeutics.
The Scrip Awards provide the industry with an opportunity to acknowledge its highest achievers across all parts of the industry and to recognize both corporate and individual achievement. Finalists will be recognized and an overall category winner named at the 13th Annual Scrip Award celebration in London, UK on November 29, 2017.
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its physician-led, high-science, and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,500 people across 35 countries.